Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
08/2003
08/21/2003US20030158244 Methods of treatment using a gastric retained losartan dosage
08/21/2003US20030158242 Salt with a sugar substitute, especially saccharin, cyclamate or acesulfame.
08/21/2003US20030158237 Combination of antioxidant substances for the treatment of alzheimer's disease
08/21/2003US20030158230 Povidone or copovidone binder; HCl-free or non-hygroscopic filler; oral dosage form; serotonin reuptake inhibition
08/21/2003US20030158206 Sildenafil mesylate for the treatment of male erectile dysfunction or female sexual disorders.
08/21/2003US20030158201 Method for treating septic shock
08/21/2003US20030158158 1 alpha, 25-dihydroxy-22-oxavitamin D3 (OCT) and a pH modifier, excellent stability; in vitro differentiation inducing activity, useful for treating secondary hyperparathyroidism, psoriasis and other diseases
08/21/2003US20030158154 Vitamin D derivative is selected from calcitriol, alphacalcidol, 24,25-dihydroxy vitamin D3, and calcifediol, and bisphosphonate such as alendronic acid or salts or hydratess for bone disorders; improved combination
08/21/2003US20030158127 Aromatic sulfenates for type I phototherapy
08/21/2003US20030158125 Polysaccharidic esters of n-derivatives of glutamic acid
08/21/2003US20030158122 For treatment of hyperlipidemia and blood coagulation disorders and to reduce levels of virus, bacteria, and endotoxins in blood stream
08/21/2003US20030158097 P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
08/21/2003US20030158087 Novel use of fulmonary surfactant for the prophylaxis or early treatment if acute fulmonary diseases
08/21/2003US20030157327 Useful as distinct tagging agents or as encoders in procedures utilizing fluorescence-based detection such as microarrays, high-throughput screening, immunoassays, and flow cytometry
08/21/2003US20030157326 For sustained release of drugs
08/21/2003US20030157196 Compositions and methods for creating an air release mechanism to maintain skin health
08/21/2003US20030157187 Compositions and methods for treating or preventing inflammatory diseases
08/21/2003US20030157184 Preparation of powder agglomerates
08/21/2003US20030157183 Method for encapsulating fine solid particles in the form of microcapsules
08/21/2003US20030157182 Pharmaceutical preparations and their manufacture
08/21/2003US20030157181 Nanocapsules having a polyelectrolyte envelope
08/21/2003US20030157180 Suitable as depot formulation for administration via intramuscular or subcutaneous injection
08/21/2003US20030157179 Use of magnetic particles
08/21/2003US20030157178 Injectable depot composition
08/21/2003US20030157177 In combination with a matrix vehicle selected from glycerol esters, hydrogenated oils, esterified polyethylene glycols, waxes and their mixtures
08/21/2003US20030157174 Having an enteric coat outside of a core particle and having an inner layer inside of the enteric coat and/or an outer layer outside of the enteric coat which comprises a water repellent agent in the inner layer and/or the outer layer
08/21/2003US20030157173 Timed, sustained release systems for propranolol
08/21/2003US20030157172 Pharmaceutical suspension for oral administration
08/21/2003US20030157171 Chitosan-xanthane hydrogel including in its matrix a poorly water soluble drug which upon swelling of hydrogel in aqueous medium becomes at least partially solubilized and releasable therefrom
08/21/2003US20030157170 Micellar drug delivery vehicles and precursors thereto and uses thereof
08/21/2003US20030157169 Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride
08/21/2003US20030157168 Comprises releasable opioid agonist (morphine); for prevention of abuse
08/21/2003US20030157167 Oxymorphone controlled release formulations
08/21/2003US20030157166 Controlled release sulfonylurea formulation
08/21/2003US20030157165 Stable saccharide-free tablets comprising a salt of quinapril or moexipril
08/21/2003US20030157164 Comprises probiotic microorganisms (lactic acid producing bacteria) and oligosaccharides (fructose, inulin), for normalizing/balancing bacterial flora present in the stomach and intestines
08/21/2003US20030157163 Semipermeable walled container housing capsule comprising progestin and estrogen for sustained-release via osmotic pressure changes within
08/21/2003US20030157162 Suspending opioid in buffer, overlaying onto lipid film, sonicating, freezing liposome mixture over dry ice and isopropanol, then freeze-drying for rehydration
08/21/2003US20030157161 Such as paclitaxel dispersed in micelle or liposome
08/21/2003US20030157160 Vaccine for modulating between T1 and T2 immune responses
08/21/2003US20030157159 Prevention and treatment of digestive tract infections
08/21/2003US20030157158 Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier
08/21/2003US20030157157 Such as progestins and estrogens; comprises sodium hydroxide as release agent; hormone replacement therapy; female contraception
08/21/2003US20030157156 Such as sodium hydroxide; sustained release; side effect reduction; urogenital disorders
08/21/2003US20030157155 Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients
08/21/2003US20030157153 Tablets based on dissolution profiles, for once a day dosing without causing drug-induced hepatotoxicity
08/21/2003US20030157146 Mixing with lactitol to synergistically increase immunoglobulin concentration in gut; side effect reduction
08/21/2003US20030157140 Parenteral preparation having structure of basement polymer layer, carrying layer containing objective substances selected from drugs, aroma chemicals, antigens; carrying layer sandwiched between basement and surface layers
08/21/2003US20030157138 Pharmaceutical or cosmetic carrier or composition for topical application onto skin and/or mucosal membranes; treatment of skin diseases or disorders including eczema, psoriasis and dermatitis
08/21/2003US20030157137 Emulsified skin care composition containing salicylic acid, lanolin oil, and propylene glycol
08/21/2003US20030157123 Chlamydia membrane ATPase and corresponding DNA molecules, which can be used to prevent and treat Chlamydia infection in mammals such as humans
08/21/2003US20030157088 Mixture of enzyme and enzyme inhibitors
08/21/2003US20030157083 Mixture with gelatin capsules; low temperature; human absorption
08/21/2003US20030157078 Identification of a pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell
08/21/2003US20030157055 Modified cytokines for use in cancer therapy
08/21/2003US20030157036 Topical dapsone for the treatment of acne
08/21/2003US20030157032 Antihistamines, bronchodilator agents, antiinflammatory agents; mixture of drug and propellant
08/21/2003US20030157031 Drug delivery; to human or animal tissues; critical temperature, pressure
08/21/2003US20030157030 Methods and compositions for therapeutic use of rna interference
08/21/2003US20030157029 Methods of administering and enhancing absorption of pharmaceutical agents
08/21/2003US20030157028 Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
08/21/2003US20030155689 Mixing metal or ceramic powder, drugs with polymer; heating to crosslink, solidification, molding
08/21/2003DE20116083U1 Plaster for transdermal release of active substance(s) has the substance loaded on a molecular sieve which has been partially dehydrated to reduce its water of crytallisation content
08/21/2003CA2516331A1 Combination therapy using glycosaminoglycans and therapeutic agents for the treatment of respiratory disorders
08/21/2003CA2476131A1 Composition for skin healing comprising a chitosan hydrogel
08/21/2003CA2476120A1 Methods and compositions for the treatment of eye diseases
08/21/2003CA2475928A1 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003CA2475722A1 Formulations of atorvastatin stabilized with alkali metal additions
08/21/2003CA2475659A1 Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation
08/21/2003CA2475592A1 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
08/21/2003CA2475544A1 Oral dosage form for controlled drug release
08/21/2003CA2475102A1 Stabilized synthetic immunogen delivery systems
08/21/2003CA2474943A1 Sugar stabilized antibody-containing solution formulations
08/21/2003CA2474626A1 Carboxylic acid compounds for use as surfactants
08/21/2003CA2473569A1 Tablets having improved tabletting characteristics and process for producing the same
08/21/2003CA2472956A1 Formulation strategies in stabilizing peptides in organic solvents and in dried states
08/21/2003CA2472744A1 Oral solid solution formulation of a poorly water-soluble active substance
08/21/2003CA2466696A1 Micromesh interproximal devices
08/20/2003EP1336600A2 Dimer-selective RXR modulators and methods for their use
08/20/2003EP1336410A1 Protein injection preparations
08/20/2003EP1336408A1 Water-soluble liquid internal medicine
08/20/2003EP1336405A1 Formulations of atorvastatin stabilized with alkali metal additions
08/20/2003EP1336404A1 Ophthalmic emulsion composition
08/20/2003EP1336341A2 Water dispersible compositions containing natural hydrophilic, water-insoluble pigments, methods of preparing same and their use
08/20/2003EP1336338A1 Foam composition and its production
08/20/2003EP1335921A1 Novel photosensitizers of 9-hydroxypheophorbide-a derivatives used for photocynamic therapy
08/20/2003EP1335771A2 Methods and instruments for treating pseudoarthrosis
08/20/2003EP1335764A2 Devices, systems and methods for patient infusion
08/20/2003EP1335759A1 Porous polymeric biomaterials, preparation method and uses
08/20/2003EP1335747A1 A composition of sodium channel blocking compound
08/20/2003EP1335743A1 Inhibition or reversal of skin aging by actin-sequestering peptides
08/20/2003EP1335729A2 Inhalative solution formulation containing a tiotropium salt
08/20/2003EP1335728A1 Novel medicament compositions based on tiotropium salts and on salmeterol salts
08/20/2003EP1335715A2 Skin friendly active ingredient plaster for transdermal administration of rubefacient active ingredients
08/20/2003EP1335714A2 Skin friendly active ingredient plaster for especially transdermal administration of etheric oils
08/20/2003EP1335713A2 Flexible barrier film for a support material for medical applications
08/20/2003EP1335712A2 Multilayered supporting construction for plaster systems containing an active ingredient
08/20/2003EP1335711A2 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
08/20/2003EP1335710A2 Soft capsules comprising a starch mixture having a reduced branching degree
08/20/2003EP1335709A2 Capsule of cellulose derivatives such as hpmc containing benzimidazole derivatives such as omeprazole
1 ... 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 ... 2991